Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2013 February;79(2) > Minerva Anestesiologica 2013 February;79(2):185-93

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ANESTESIOLOGICA

A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036


eTOC

 

REVIEWS  


Minerva Anestesiologica 2013 February;79(2):185-93

language: English

Rituximab in critically ill patients

Dimopoulos G. 1, Armaganidis A. 1, Poulakou G. 2, Matthaiou D. K. 2

1 Department of Critical Care, Medical School, University of Athens, “Attikon” University Hospital, Athens, Greece;
2 .4th Department of Internal Medicine, Medical School, University of Athens, “Attikon” University Hospital, Athens, Greece


FULL TEXT  


Rituximab is a monoclonal chimeric antibody used in the treatment of CD20-positive B-cell malignancies and rheumatoid arthritis. However, it is used in several other off-label indications including acute graft-versus-host disease. We sought to critically examine the role of rituximab in the treatment of acute graft versus host disease (aGVHD) in critically ill patients and the potential associations with infectious complications in transplant recipients.

top of page

Publication History

Cite this article as

Corresponding author e-mail

gdimop@med.uoa.gr